Wedbush upgraded Meridian Biosciences (NASDAQ: VIVO) from Underperform to Neutral with a price target of $21.00 (from $17.00). Analyst ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE